# Kamada (KMDA) — News

KMDA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/kmda/news

## Recent headlines

- [Plans for KNDs IPO put on hold for now, source familiar with matter says](https://www.ainvest.com/news/plans-knds-ipo-put-hold-source-familiar-matter-2610) — AInvest Wire, Oct 14, 2026
  Defense company KNDS has temporarily paused its plans for an initial public offering (IPO), according to a source familiar with the matter . The company had previously announced its intention to list shares in Paris and Frankfurt as part of a strategy to support long-term growth . The IPO was…
- [Renk, KNDs sign Leopard 2 contract extension worth around EUR 130M](https://www.ainvest.com/news/renk-knds-sign-leopard-2-contract-extension-worth-eur-130m-2610) — AInvest Wire, Oct 14, 2026
- [Trading halted: (NMDR) Due to limit-up limit-down trading pause](https://www.ainvest.com/news/trading-halted-nmdr-due-limit-limit-trading-pause-2610) — AInvest Wire, Oct 12, 2026
  Trading in shares of NanoMed Dynamics, Inc. (NMDR) has been temporarily halted due to the activation of a limit-up limit-down mechanism, a regulatory measure designed to prevent excessive volatility and ensure orderly trading conditions. The pause was implemented following exceeded predefined…
- [Kamada targets $20M-$25M biosimilar revenue/yr by 2030](https://www.ainvest.com/news/kamada-targets-20m-25m-biosimilar-revenue-yr-2030-2610) — AInvest Wire, Oct 6, 2026
  Kamada, a biopharmaceutical company, has outlined its financial goals for the coming years, including a target of generating $20 million to $25 million annually in biosimilar revenue by 2030. This projection reflects the company’s strategic focus on expanding its biosimilar portfolio and…
- [Kamada Ltd.: Expects commercial availability of at least two additional biosimilar products during 2027](https://www.ainvest.com/news/kamada-expects-commercial-availability-additional-biosimilar-products-2027-2610) — AInvest Wire, Oct 6, 2026
  Kamada Ltd. (NASDAQ: KMDA) has outlined plans for the commercial availability of at least two additional biosimilar products during 2027, as part of its ongoing expansion in the biosimilar market. The company has already launched two biosimilar products in the Israeli market and is introduce two…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).